By the Committees on Rules; Governmental Oversight and Accountability; and Health Policy; and Senator Clemens

595-04442-17 2017840c3

A bill to be entitled

An act relating to controlled substance prescribing; providing legislative findings; requiring that specified physicians who are registered with the United States Drug Enforcement Administration to prescribe controlled substances complete a continuing education course before a certain date; specifying requirements for the continuing education course; authorizing the course to be offered in a distance learning format; creating grounds for disciplinary actions for failure to meet the course requirements; providing that completion of the course is a condition of licensure renewal as of a certain date; amending s. 893.055, F.S.; revising requirements for reporting the dispensing of controlled substances; limiting an exception to reporting requirements for certain facilities that dispense controlled substances; authorizing certain employees of the United States Department of Veterans Affairs access to certain information in the prescription drug monitoring program database; specifying when a revised reporting requirement takes effect; providing effective dates.

2223

1

2

3

4

5

6

7

8

9

10

11

12

13

1415

1617

18

19

20

21

Be It Enacted by the Legislature of the State of Florida:

242526

27

28

29

Section 1. The Legislature finds that the road to drug addiction may begin as early as 3 days after the initiation of opioid treatment for acute pain. Because of the potentially devastating effects of such addiction, the Legislature also

595-04442-17 2017840c3 30 finds that awareness of this potentially life-threatening 31 problem must be raised among Florida's practitioners. Before December 31, 2017, each physician licensed pursuant to chapter 32 458, Florida Statutes, or chapter 459, Florida Statutes, who is 33 34 registered with the United States Drug Enforcement 35 Administration to prescribe controlled substances pursuant to 21 36 U.S.C. s. 822 shall complete a 2-hour continuing education 37 course offered by a statewide professional association of 38 physicians in this state which is accredited to provide 39 educational activities designated for the American Medical 40 Association Physician's Recognition Award (AMA PRA) Category 1 41 Credit or the American Osteopathic Association (AOA) Category 1-A continuing medical education (CME) credit. The course must 42 43 contain information on the current standards regarding opiate 44 prescribing and alternatives to these standards, and information 45 on the risks of opioid addiction following even brief periods of 46 treatment in the management of acute pain. The course may be 47 offered in a distance learning format and must be included within the number of continuing medical education hours required 48 49 by law. Failure to complete the course before December 31, 2017 50 constitutes grounds for disciplinary action under s. 51 456.072(1)(e), Florida Statutes, and chapter 458, Florida Statutes, or chapter 459, Florida Statutes, as applicable. 52 Effective January 1, 2020, completion of this course is required 53 54 as a condition of licensure renewal for every physician 55 registered with the United States Drug Enforcement 56 Administration to prescribe controlled substances. 57 Section 2. Subsection (4), paragraph (g) of subsection (5), 58 and paragraphs (a) and (b) of subsection (7) of section 893.055,

595-04442-17 2017840c3

Florida Statutes, are amended to read:

893.055 Prescription drug monitoring program.-

- (4) Each time a controlled substance is dispensed to an individual, the controlled substance shall be reported to the department through the system as soon thereafter as possible, but no later than the close of the next business day not more than 7 days after the day date the controlled substance is dispensed unless an extension is approved by the department for cause as determined by rule. A dispenser must meet the reporting requirements of this section by submitting via the departmentapproved electronic system providing the required information concerning each controlled substance that it dispensed in a departmentapproved, secure methodology and format. Such approved formats may include, but are not limited to, submission via the Internet, on a disc, or by use of regular mail.
- (5) When the following acts of dispensing or administering occur, the following are exempt from reporting under this section for that specific act of dispensing or administration:
- (g) A rehabilitative hospital, assisted living facility, or nursing home dispensing a certain dosage of a controlled substance, as needed, to a patient while the patient is present and receiving care as ordered by the patient's treating physician.
- (7) (a) A practitioner or pharmacist who dispenses a controlled substance must submit the information required by this section in an electronic or other method in an ASAP format approved by rule of the department unless otherwise provided in this section. The cost to the dispenser in submitting the information required by this section may not be material or

88

89

90

91

92

93

94

95

9697

98

99

100

101102

103

104

105

106

107

108

109

110

111

112

113

114115

116

595-04442-17 2017840c3

extraordinary. Costs not considered to be material or extraordinary include, but are not limited to, regular postage, electronic media, regular electronic mail, and facsimile charges.

(b) A pharmacy, prescriber, or dispenser, or the designee of a pharmacy, prescriber, or dispenser, shall have access to information in the prescription drug monitoring program's database which relates to a patient of that pharmacy, prescriber, or dispenser in a manner established by the department as needed for the purpose of reviewing the patient's controlled substance prescription history. An employee of the United States Department of Veterans Affairs who provides health care services pursuant to such employment and who has the authority to prescribe controlled substances shall have access to the information in the program's database in a manner established by the department. Such access is limited to the information that relates to a patient of such employee and may be accessed only for the purpose of reviewing the patient's controlled substance prescription history. Other access to the program's database shall be limited to the program's manager and to the designated program and support staff, who may act only at the direction of the program manager or, in the absence of the program manager, as authorized. Access by the program manager or such designated staff is for prescription drug program management only or for management of the program's database and its system in support of the requirements of this section and in furtherance of the prescription drug monitoring program. Confidential and exempt information in the database shall be released only as provided in paragraph (c) and s. 893.0551. The

595-04442-17 2017840c3

program manager, designated program and support staff who act at the direction of or in the absence of the program manager, and any individual who has similar access regarding the management of the database from the prescription drug monitoring program shall submit fingerprints to the department for background screening. The department shall follow the procedure established by the Department of Law Enforcement to request a statewide criminal history record check and to request that the Department of Law Enforcement forward the fingerprints to the Federal Bureau of Investigation for a national criminal history record check.

Section 3. The requirement in s. 893.055(4), Florida

Statutes, as amended by this act, that the dispensing of a controlled substance be reported to the Department of Health no later than the next business day shall take effect January 1, 2018.

Section 4. Except as otherwise expressly provided in this act, this act shall take effect July 1, 2017.